Abstract
The Food and Drug Administration (FDA) is cracking down on marketing of cannabidiol (CBD). There is one medication — Epidiolex — that is approved for rare epilepsy in children (seizures associated with Lennox‐Gastaut syndrome or Dravet syndrome in patients 2 years of age and older). Beyond that, no CBD products have been approved by the FDA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Brown University Child and Adolescent Behavior Letter
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
